RxDoctor Payments Data

Anuradha Ramaswamy, MD

Pulmonary Disease · Warwick, RINPI 1023113644

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Intuitive Surgical at 45.5% of the total.

$3,138in general payments, 2019–2025

Across 23 payments — averaging $136.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Gyrus ACMI, Inc.$1K
  • Baxter Healthcare$143
  • Pinnacle Biologics, Inc$61
  • Pulmonx Corporation$61
  • GSK$32

What the payments were for

  • Consulting fees$84827%
  • Travel & lodging$1,75556%
  • Food & beverage$53517%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,138 in reported general payments places this provider in the 75th percentile of 59 pulmonary disease providers in Rhode Island.

See all pulmonary disease providers in Rhode Island

Medicare billing

Part B allowed, 2024
$45,656
Medicare patients
219
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab25$181,878
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$156,830
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$46,267
Incruse ElliptaUmeclidinium Bromide90$36,957
Spiriva RespimatTiotropium Bromide39$24,248
Spiriva HandihalerTiotropium Bromide29$18,765
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$17,588
Advair HfaFluticasone Propion/Salmeterol40$17,121
Breo ElliptaFluticasone/Vilanterol31$14,017
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$8,239
Arnuity ElliptaFluticasone Furoate15$6,657
Wixela InhubFluticasone Propion/Salmeterol51$6,545
SymbicortBudesonide/Formoterol Fumarate26$6,057
Advair DiskusFluticasone Propion/Salmeterol17$5,494
Albuterol Sulfate HfaAlbuterol Sulfate134$4,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta$32$413,928411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 pulmonary disease providers in Rhode Island.

Other pulmonary disease in Warwick

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →